Madrigal Pharmaceuticals, Inc. MDGL Total debt
Total debt at other companies
Other financials
Where this comes from
Calculated from Madrigal Pharmaceuticals, Inc.’s reported figures.
Plus components not separately reported this period.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s total debt?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported total debt of $377.3M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s total debt changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s total debt increased by 187.2% year-over-year, from $131.37M to $377.3M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s total debt?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s total debt has grown at a 238.2% compound annual growth rate (CAGR), from $786K to $347.63M.
- What does total debt mean?
- The total amount of money the company owes to banks, bondholders, and other lenders.
- How do you interpret total debt?
- An increase in total debt suggests higher financial leverage and increased interest expense, which may heighten insolvency risk for pre-revenue companies. A decrease indicates deleveraging or the repayment of obligations, potentially improving the company's balance sheet health.
- How does total debt compare across companies?
- Peers in the clinical-stage biotech sector often maintain low debt levels to preserve cash for R&D, though some may utilize debt financing to extend their cash runway during late-stage clinical trials.